HURA TuHURA Biosciences, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
HURA
—
—
Key stats
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 22
- List Date
- 2024-10-18
- CIK
- 0001498382
- Next Earnings
- 2026-11-13
- EPS Forecast
- ($0.14) (3 est.)
- Headquarters
- Tampa, FL
- Homepage
- https://www.tuhurabio.com
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 21.41% | -28.61% | -3.60% |
| Feb | -- | -50.31% | 221.83% | 85.76% |
| Mar | -- | 49.54% | 17.76% | 33.65% |
| Apr | -- | 29.90% | 38.27% | 34.09% |
| May | -- | -21.54% | -3.00% | -12.27% |
| Jun | -- | -28.53% | 4.46% | -12.04% |
| Jul | -- | 0.40% | -11.79% | -5.69% |
| Aug | -- | 12.50% | -0.47% | 6.01% |
| Sep | -- | -4.25% | 3.45% | -0.40% |
| Oct | -9.68% | 0.39% | 3.03%* | -2.09% |
| Nov | 7.72% | -21.26% | -- | -6.77% |
| Dec | -26.17% | -58.87% | -- | -42.52% |
| Total | -28.17% | -76.89% | 254.71% | 49.88% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.93
SMA 50: $2.04
SMA 200: $1.95
Current: $2.04
EMA 12: $1.96
EMA 26: $1.97
MACD: -0.0112 | Signal: 0.0340
BEARISH
ADX (14): 17.50
RANGE
+DI: 25.73
−DI: 16.90
Momentum Oscillators
RSI (14): 53.02
NEUTRAL
Stoch %K: 73.53
Stoch %D: 71.02
Williams %R: -36.54
Volume & Volatility
BB Upper: $2.18
BB Lower: $1.69
NEUTRAL
OBV: -7,113,308
Vol SMA 20: 329,602
Vol ROC: 272.13%
ATR: $0.15
True Range: $0.30
HV 20: 86.8%
HV 30: 73.3%
HV 60: 69.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: BEARISH (confidence level 6/10)
Key drivers:
- Bearish momentum signals from MACD
- Trend weakness in short-term and medium-term indicators
- High volatility and significant beta exposure
Primary risks:
- Potential breakdown below $1.82 support
- Increased risk of further declines with high volatility
Investment thesis: The stock is likely to experience continued price pressure due to bearish momentum signals, trend weakness, and high volatility.
Recent news sentiment impact: Positive headlines from TuHURA R&D Jumps 75% in Q2 may not be enough to counteract the bearish technical signals.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): BEARISH; Medium-term (1-3 months): NEUTRAL; Long-term (3-12 months): BEARISH
Support/Resistance Levels: Key price levels from moving averages:
- Lower Bollinger Band: $1.95
- SMA 20: $2.18
- SMA 50: $2.21
Momentum Signals:
- RSI interpretation: NEUTRAL (48.93)
- MACD signal: BEARISH (crossover below signal line)
- Bollinger Bands position: NEUTRAL (price near middle band)
Volume Analysis: Volume trends and institutional interest signals:
- On-Balance Volume (OBV): -6788824.08 (bearish)
- Volume Rate of Change: -4.47% (bearish)
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- Positive headlines on TuHURA R&D Jumps 75% in Q2 and Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years
- Neutral headlines on shareholder investigations
Sentiment Assessment: Aggregate news sentiment: POSITIVE (65%)
Catalyst Identification: Upcoming events, earnings, product launches:
- No specific catalysts identified due to lack of recent news and earnings data
Market Narrative: How news aligns with or contradicts technical signals:
- Positive news may not be enough to counteract bearish technical signals
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market: HIGH (beta 3.18 vs SPY)
Volatility Regime: Current vs historical volatility levels: HIGH VOLATILITY (1.30)
Options Market Signals: IV rank, put/call ratios, unusual activity:
- No options data available
Downside Protection: Support levels and risk management considerations:
- SMA 20: $2.18
- SMA 50: $2.21
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- HURA is underperforming the market (SPY)
Institutional Activity: Volume patterns suggesting institutional interest signals:
- On-Balance Volume (OBV) indicates bearish institutional activity
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- Correlation: 0.31 (low correlation with market)
Relative Valuation: Position within trading range:
- HURA is currently below its historical mean price level
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- Lower Bollinger Band: $1.95
- SMA 20: $2.18
- SMA 50: $2.21
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Breakout above SMA 20: $2.18 (bullish)
- Breakdown below Lower Bollinger Band: $1.95 (bearish)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- No specific catalysts identified due to lack of recent news and earnings data
Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss at SMA 20: $2.18
- Consider reducing position size or hedging with options
Generated
News
All HURA news →
HURA Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 3.1209
Alpha: 27.17%
Correlation: 0.3045
R-Squared: 9.3%
Stock Volatility: 130.6%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
HURA Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
HURA Insider Trading (Form 4)
Latest: 2026-05-29Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-05-29 | James A. Bianco | Chief Executive Officer | Gift (G) | −150,000 | — | EDGAR | |
| 2026-02-17 | George K Ng | Director | Grant (A) | +156,240 opt | — | EDGAR | |
| 2026-02-17 | James S J Manuso | Director | Grant (A) | +156,240 opt | — | EDGAR | |
| 2026-02-17 | Robert E. Hoffman | Director | Grant (A) | +156,240 opt | — | EDGAR | |
| 2026-02-17 | Craig Tendler | Director | Grant (A) | +156,240 opt | — | EDGAR | |
| 2026-02-17 | Alan List | Director | Grant (A) | +156,240 opt | — | EDGAR | |
| 2026-01-08 | James A. Bianco | Chief Executive Officer | Grant (A) | +610,332 opt | — | EDGAR | |
| 2026-01-08 | Dan Dearborn | Chief Financial Officer | Grant (A) | +273,696 opt | — | EDGAR | |
| 2025-12-17 | James A. Bianco | Chief Executive Officer | Grant (A) | +3,414,891 opt | — | EDGAR | |
| 2025-12-17 | Dan Dearborn | Chief Financial Officer | Grant (A) | +1,531,367 opt | — | EDGAR | |
| 2025-03-19 | Craig Tendler | Director | Grant (A) | +151,883 opt | — | EDGAR | |
| 2025-01-06 | Alan List | Director | Grant (A) | +51,275 opt | — | EDGAR | |
| 2025-01-06 | George K Ng | Director | Grant (A) | +51,275 opt | — | EDGAR | |
| 2025-01-06 | Robert E. Hoffman | Director | Grant (A) | +51,275 opt | — | EDGAR | |
| 2025-01-06 | James S J Manuso | Director | Grant (A) | +59,590 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
HURA Insider Holdings
1 insider · @ $2.04
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | James A. Bianco | Chief Executive Officer | 2,173,307 | $4.43M | $0 | 5 | 2026-05-29 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
HURA Board & Officers
As of SEC filings through May 29, 2026Directors 6
- Robert E. Hoffman · since Apr 11, 2018
- Alan List · since Oct 18, 2024
- George K Ng · since Oct 18, 2024
- James A. Bianco · since Oct 18, 2024
- James S J Manuso · since Oct 18, 2024
- Craig Tendler · since Mar 10, 2025
Officers 2
- James A. Bianco · Chief Executive Officer · since Oct 18, 2024
- Dan Dearborn · Chief Financial Officer · since Oct 18, 2024
Changes in the last 10 years (34)
| May 5, 2025 | The company announced the departure of Dennis Yamashita as Chief Scientific Officer in an SEC filing |
| Mar 10, 2025 | Craig Tendler became a director |
| Jan 6, 2025 | Robert E. Hoffman no longer listed as President and CEO in SEC filings |
| Oct 18, 2024 | Vijay Patel became a 10% owner |
| Oct 18, 2024 | The company announced the departure of Tamara A Favorito from the board in an SEC filing |
| Oct 18, 2024 | The company announced the departure of Robert Joseph Toth Jr from the board in an SEC filing |
| Oct 18, 2024 | The company announced the departure of Laura L. Johnson from the board in an SEC filing |
| Oct 18, 2024 | James S J Manuso became a director |
| Oct 18, 2024 | James A. Bianco became a director |
| Oct 18, 2024 | James A. Bianco became Chief Executive Officer |
| Oct 18, 2024 | George K Ng became a director |
| Oct 18, 2024 | Dennis Yamashita became Chief Scientific Officer |
| Oct 18, 2024 | Dan Dearborn became Chief Financial Officer |
| Oct 18, 2024 | Alan List became a director |
| Nov 20, 2023 | The company announced the departure of Dennis M Brown as Chief Scientific Officer in an SEC filing |
| May 30, 2023 | The company announced the departure of Anthony Scott Praill as Chief Financial Officer in an SEC filing |
| May 20, 2022 | The company announced the departure of Saiid Zarrabian from the board in an SEC filing |
| Feb 4, 2022 | The company announced the departure of Keith Murphy from the board in an SEC filing |
| Nov 10, 2021 | Robert E. Hoffman first listed as President and CEO in an SEC filing |
| Nov 8, 2021 | The company announced the departure of Saiid Zarrabian as President and CEO in an SEC filing |
| Oct 25, 2021 | The company announced the departure of John Liatos as SVP, Business Development in an SEC filing |
| Apr 29, 2021 | Tamara A Favorito became a director |
| Aug 19, 2020 | Keith Murphy became a director |
| Aug 19, 2020 | John Liatos became a director |
| Aug 19, 2020 | John Liatos became SVP, Business Development |
| Jun 30, 2020 | John K Bell reported in an SEC filing no longer being a director |
| Jun 26, 2020 | Laura L. Johnson became a director |
| Jul 3, 2018 | Dennis M Brown no longer listed as a director in SEC filings |
| Jun 22, 2018 | Napoleone Ferrara became a director |
| May 22, 2018 | Saiid Zarrabian listed as President and CEO (previously Interim CEO) in SEC filings |
| Apr 11, 2018 | Robert E. Hoffman became a director |
| Jan 3, 2018 | Jeffrey Bacha no longer listed as CEO in SEC filings |
| Nov 7, 2017 | Saiid Zarrabian first listed as Interim CEO in an SEC filing |
| Jul 7, 2017 | Saiid Zarrabian became a director |
Not reported recently (6)
- Vijay Patel · Last reported as a 10% owner in an SEC filing dated Oct 22, 2024
- John Liatos · Last reported as a director in an SEC filing dated Sep 17, 2020
- Lynda Sarah Cranston · Last reported as a director in an SEC filing dated Jun 30, 2020
- Napoleone Ferrara · Last reported as a director in an SEC filing dated Jun 30, 2020
- Jeffrey Bacha · Last reported as a director in an SEC filing dated Apr 3, 2018
- Erich Mohr · Last reported as a director in an SEC filing dated Apr 3, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
3 ETFs hold HURA
3 shown · $4.95M total exposure · 0.02% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.